1. FRI0137 Efficacy, safety and immunogenicity from week 30 to week 54 in a randomised, double-blind phase iii study comparing a proposed infliximab biosimilar (PF-06438179/GP1111) with reference infliximab. (12th June 2018) Authors: Alten, R.; Tseluyko, V.; Hala, T.; Mehmedagic, S.; Pileckyte, M.; Dokoupilová, E.; Jovic, D.; Rehman, M.; Zhang, M.; Sewell, L.; Hackley, S.; Salts, S.; Cronenberger, C.; Schumacher, K.; von Richter, O.; Batko, B. Journal: Annals of the rheumatic diseases Issue: Volume 77(2018)Supplement 2 Page Start: 612 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. FRI0161 Sustained Efficacy and Comparable Safety and Immunogenicity after Transition To SB5 (An Adalimumab Biosimilar) vs Continuation of The Adalimumab Reference Product in Patients with Rheumatoid Arthritis: Result of Phase III Study. (15th July 2016) Authors: Weinblatt, M.; Baranauskaite, A.; Niebrzydowski, J.; Dokoupilova, E.; Zielinska, A.; Sitek-Ziolkowska, K.; Jaworski, J.; Racewicz, A.; Pileckyte, M.; Jedrychowicz-Rosiak, K.; Zhdan, V.; Cheong, S.Y.; Ghil, J. Journal: Annals of the rheumatic diseases Issue: Volume 75(2016)Supplement 2 Page Start: 487 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. THU0182 A comparative clinical study of pf-06410293, a candidate adalimumab biosimilar, and reference adalimumab for the treatment of active rheumatoid arthritis. (12th June 2018) Authors: Alten, R.; Fleischmann, R.M.; Pileckyte, M.; Hua, S.Y.; Cronenberger, C.; Bock, A.E.; Sewell, K.L. Journal: Annals of the rheumatic diseases Issue: Volume 77(2018)Supplement 2 Page Start: 309 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗